Global Health Innovative Technology (GHIT) Fund
Active Since: 2013
Contributing to SDGs…
Japanese-led initiative aiming to discover and advance the development of new health technologies such as drugs, vaccines and diagnostic for low-and middle-income countries.
Global Health Innovation Technology Fund.
Academia or research institute
Liverpool School of Tropical Medicine
Bio21 Molecular Science and Biotechnology Institute
St. Jude Childrens Research Hospital
Sabin Vaccine Institute
KEMRI-Wellcome Trust Research Program
Noguchi Memorial Institute for Medical Research
The Scripps Research Institute
Kumamoto National Institute of Technology, Kumamoto College
Fujita Health University
Keio University School of Medicine
Research Institute for Microbial Diseases, Osaka University
University of Toyama
Toyama Prefectural University
Jichi Medical University
Tokyo Medical and Dental University
National Research Center for Protozoan diseases, Obihiro University of Agriculture and Veterinary Medicine
Institute of Microbial Chemistry
Institute of Physical and Chemical Research (RIKEN)
National Science and Technology Development Agency
National Institute of Biomedical Innovation, Health and Nutrition
National Institute of Advanced Industrial Science and Technology
National Institute of Infectious Diseases
Research Institute of Tuberculosis
The Chemo-Sero-Therapeutic Research Institute
The Kitazato Institute
Medical Center for Translational Research Osaka University Hospital
Charité –Universitätsmedizin Berlin
Johns Hopkins University
Leiden University Medical Center
Penn State Hershey Medical Center
The Ohio State University
The Ohio University
Trustees of Dartmouth College Geisel School of Medicine
Universidad Autònoma Juan Misael Saracho
Universidad de Concepción, Chile (UC)
Universidad Mayor de San Simon
Universidad Nacional de La Plata (UNLP)
Universite Felix Houphouet-Boigny
University of Buea
University at Buffalo, The State University of New York
University of California, San Diego (UCSD)
University of Cambridge
University of Chicago
University of Copenhagen (UCPH)
University of Dundee
University of Florida
University of Kentucky
University of Liverpool
University of Melbourne
University of Minnesota
University of Pennsylvania
University of the Philippines- Manila, Philippines
University of Tübingen (UKT)
Biomedical Primate Research Centre
Center for Health Promotion and Research (CHPR)
Centre de Recherches Médicales de Lambaréné (CERMEL)
Centre National de Recherche et de Formation sur le Paludisme (CNRFP)
Centro para el Desarrollo de Investigación Científica (CEDIC)
Groupe de Recherche Action en Santé (GRAS)
Hospital General de Mexico
Ifakara Health Institute
Institut de recherche pour le développement
Institut national de la santé et de la recherche médicale (Inserm)
Instituto de Nutrición “Salvador Zubirán” México (IN)
Instituto Leonidas & Maria Deane
International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B)
Mycetoma Research Center (MRC)
High Energy Accelerator Research Organization (KEK)
Baylor College of Medicine
Colorado State University
London School of Hygiene and Tropical Medicine
Muhimbili University of Health and Allied Sciences in Tanzania
Universiti Sains Malaysia
University of Bonn
University of Massachusetts
Barcelona Institute for Global Health (ISGLOBAL)
Centre Pasteur du Cameroon (CPC)
Institut de Recherche en Sciences de la Santé (IRSS), Burkina Faso
Pasteur Institute Côte d’Ivoire
Insititute of Tropical Medicine Antwerp
Collective of Applied Studies and Social Development
National Center for Genetic Engineering and Biotechnology (BIOTEC), Thailand
Walter and Eliza Hall Institute of Medical Research
US Food and Drug Administration (US FDA)
Global Alliance for TB Drug Development (TB Alliance)
Drugs for Neglected Diseases initiative (DNDi)
Malaria No More
European Vaccine Initiative
Structural Genomics Consortium
Intergovernmental Organizations and Multilaterals
Coalition for Epidemic Preparedness Innovations (CEPI)
International Centre for Genetic Engineering and Biotechnology
International Centre for Genetic Engineering and Biotechnology
Singapore Immunology Network
Pharma (Non-IFPMA Member)
InBios International, Inc.
Private foundation or development organization
Bill and Melinda Gates Foundation
SCI Foundation (SCI)
Swiss Tropical and Public Health Institute (Swiss TPH)
Product development partnerships
Medicines for Malaria Venture (MMV)
AI Biosciences Inc.
Antigen Discovery, Inc.
ERADA Technology Alliance Ltd.
Latham BioPharm Group (Latham)
Oasis Diagnostics Corporation
Ology Bioservices Inc.
TCG Lifesciences Pvt. Limited
Other business sector
Asociación Civil Selva Amazónica
Ciencia y Estudios Aplicados Para el Desarrollo en Salud y Medio Ambiente (CEADES)
Drugs and Diagnostics for Tropical Diseases
Klinikum rechts der Isar der Technischen Universität München, Department of Neurology, (MRI)
Platform of Integral Care for Patients with Chagas Disease
Raoul Follereau Institute Côte d’Ivoire
Hope Commission International
Established in 2013, Global Health Innovative Technology (GHIT) is a Japanese-led initiative aiming to discover and advance the development of new health technologies such as drugs, vaccines and diagnostic for low-and middle-income countries.
Globalization and the unprecedented speed of cross-border infection in the 21st century has created the need for a global health strategy. Awareness of common global threats to the health of citizens has increased, and governments understand the need to work together to counteract these threats. Since 2000, the global community has focused on three of the biggest threats to human health – HIV, tuberculosis and malaria. In particular, the eradication of malaria and NTDs is listed as one of the 169 targets linked to the 17 United Nations’ Sustainable Development Goals (SDGs).
The Global Health Innovative Technology Fund (GHIT Fund), is Japan’s first public-private partnership to promote the creation of innovative treatment agents for infectious diseases that affect people in developing countries, such as malaria, tuberculosis, and neglected tropical diseases (NTDs).
The GHIT Fund was established by three key partners: the Government of Japan, the Bill & Melinda Gates Foundation and five Japanese leading pharmaceutical companies: Astellas Pharma, Daiichi Sankyo, Eisai, Shionogi, and Takeda Pharmaceutical. In 2018, there are now 11 full partners.
As the world’s first public-private partnership, GHIT Fund has facilitated research and development for neglected diseases, such as malaria, tuberculosis and NTDs. As antimicrobial resistance is also now a serious global health threat, GHIT supports AMR related projects. The combination of Japan’s government and its drug industry—the third largest in the world—brings Japan’s technology, innovation and insights to the development of drugs, vaccines and diagnostics for the developing world.
- Joint research with Medicines for Malaria Venture (MMV): The Company provided its pharmaceutical compound library (50,000 compounds) to Medicines for Malaria Venture (MMV), a research institution that focuses on the discovery of new anti-malaria drugs. Three types of promising hit compounds that have the potential to become pharmaceutical products have been identified. In addition, we promoted joint research and from one of these compounds, we acquired two lead compounds as new anti-malaria drug candidates. In April 2019, we will move to the next phase and continue conducting research in collaboration with MMV to create candidate compounds.
- Joint research with Drugs for Neglected Diseases initiative (DNDi): Together with the Drugs for Neglected Diseases initiative (“DNDi”), an international organization involved in non-profit drug development, we began drug discovery research for lead compounds targeting Chagas disease and leishmaniasis in April 2021. MTPC and DNDi have been conducting compound discovery screening for these diseases since September 2019 and succeeded in acquiring nine types of hit compounds. Since the acquired hit compounds fulfilled the criteria for advancing to the lead compound search, the next step in drug discovery, we have set the acquisition of compounds that meet the lead stage criteria as the final goal of the two-year project.
SDGs THE PARTNERSHIP CONTRIBUTES TO
SDG 3: Good Health and Wellbeing
- 3.2: Reduce Under-5 Mortality
- 3.3: Communicable Diseases & NTDs
- 3.8: Achieve universal health coverage
SDG 5: Gender Equality
SDG 9: Industry Innovation and Infrastructure
SDG 10: Reduced Inequalities
SDG 17: Partnerships for the Goals
RESULTS & MILESTONES
In 2016, GHIT Fund announced it was investing in a vaccine that could block the transmission of two species of malaria and a rapid fire test that can reveal a malaria infection in a matter of minutes. It is also investing in the development of a new diagnostic test for tuberculosis (TB) by Fujifilm Corporation and Foundation for Innovative New Diagnostics, which can diagnose TB in HIV-positive patients.
In 2015 the GHIT Fund, its members Eisai, Shionogi and Takeda Pharmaceutical, along with partners the Drugs for Neglected Diseases initiative (DNDi) and AstraZeneca began a ground-breaking initiative to accelerate and cut the cost of early stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease.
In 2013 Astellas received a $1.86 million grant to develop and register a new pediatric formulation of the gold standard treatment drug praziquantel to combat schistosomiasis.
In June 2013, with support from the GHIT Fund, Takeda began to work with Product Development Partners (PDPs), including MMV, TB Alliance and DNDi, in a program to screen Takeda’s drug compound library for new candidate compounds that might have the potential to be developed into new drugs for the treatment of infections particularly prevalent in developing countries, such as HIV, tuberculosis, malaria and neglected tropical diseases.
GHIT has provided grants of $5.7 million to six global partnerships developing innovative drugs and vaccines against malaria, tuberculosis and Chagas disease in the first round of request for proposal (RFP) in November, 2013. Another $12 million grants for TB and NTDs were awarded to four innovative projects in the second round of RFP in March, 2014.
Infectious and Parasitic Disease
- Drug-Resistant Infections (AMR)
Neglected Tropical Diseases (NTDs)
- Dengue and Chikungunya
- Chagas Disease